Advances in drug eluting stents – focus on the Endeavor® zotarolimus stent

Jonathan Bridges, Donald CutlipBeth Israel Deaconess Medical Center, Boston, Massachusetts, USAAbstract: Coronary artery disease remains one of the leading causes of death in the United States. Over the last 30 years, the development of coronary artery angioplasty and stenting has drastically reduce...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jonathan Bridges, Donald Cutlip
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://doaj.org/article/9551f77810bb4ed58f3f765e14708571
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:9551f77810bb4ed58f3f765e14708571
record_format dspace
spelling oai:doaj.org-article:9551f77810bb4ed58f3f765e147085712021-12-02T02:07:05ZAdvances in drug eluting stents – focus on the Endeavor® zotarolimus stent1179-1470https://doaj.org/article/9551f77810bb4ed58f3f765e147085712008-12-01T00:00:00Zhttp://www.dovepress.com/advances-in-drug-eluting-stents-ndash-focus-on-the-endeavorsupregsup-z-a2681https://doaj.org/toc/1179-1470Jonathan Bridges, Donald CutlipBeth Israel Deaconess Medical Center, Boston, Massachusetts, USAAbstract: Coronary artery disease remains one of the leading causes of death in the United States. Over the last 30 years, the development of coronary artery angioplasty and stenting has drastically reduced mortality during acute coronary syndromes while also reducing symptoms of chronic coronary artery disease. Unfortunately, the placement of stents in a coronary artery can be complicated by in-stent thrombosis or restenosis. In 2003–2004, a new generation of stents was introduced to the market with the goal of reducing the rate of restenosis. These stents, called drug eluting stents (DES), are coated with a pharmacological agent designed to reduce the neointimal hyperplasia associated with restenosis. Within a year, approximately 80% of all percutaneous coronary interventions performed within the US involved placement of a DES. In 2006, a controversy arose about the possibility of a statistically significant increased risk of acute stent thrombosis associated with DES especially when used for an “off label” indication. This risk was attributed to delayed endothelization. This controversy has led to a reduction in the use of DES along with longer use of dual platelet inhibition with aspirin and clopidogrel. Recently Medtronic introduced a new DES to the market called the Endeavor® stent – a zotarolimus eluting stent.Keywords: Endeavor® stent, zotarolimus stent, drug eluting stent Jonathan BridgesDonald CutlipDove Medical PressarticleMedical technologyR855-855.5ENMedical Devices: Evidence and Research, Vol 2009, Iss default, Pp 1-8 (2008)
institution DOAJ
collection DOAJ
language EN
topic Medical technology
R855-855.5
spellingShingle Medical technology
R855-855.5
Jonathan Bridges
Donald Cutlip
Advances in drug eluting stents – focus on the Endeavor® zotarolimus stent
description Jonathan Bridges, Donald CutlipBeth Israel Deaconess Medical Center, Boston, Massachusetts, USAAbstract: Coronary artery disease remains one of the leading causes of death in the United States. Over the last 30 years, the development of coronary artery angioplasty and stenting has drastically reduced mortality during acute coronary syndromes while also reducing symptoms of chronic coronary artery disease. Unfortunately, the placement of stents in a coronary artery can be complicated by in-stent thrombosis or restenosis. In 2003–2004, a new generation of stents was introduced to the market with the goal of reducing the rate of restenosis. These stents, called drug eluting stents (DES), are coated with a pharmacological agent designed to reduce the neointimal hyperplasia associated with restenosis. Within a year, approximately 80% of all percutaneous coronary interventions performed within the US involved placement of a DES. In 2006, a controversy arose about the possibility of a statistically significant increased risk of acute stent thrombosis associated with DES especially when used for an “off label” indication. This risk was attributed to delayed endothelization. This controversy has led to a reduction in the use of DES along with longer use of dual platelet inhibition with aspirin and clopidogrel. Recently Medtronic introduced a new DES to the market called the Endeavor® stent – a zotarolimus eluting stent.Keywords: Endeavor® stent, zotarolimus stent, drug eluting stent
format article
author Jonathan Bridges
Donald Cutlip
author_facet Jonathan Bridges
Donald Cutlip
author_sort Jonathan Bridges
title Advances in drug eluting stents – focus on the Endeavor® zotarolimus stent
title_short Advances in drug eluting stents – focus on the Endeavor® zotarolimus stent
title_full Advances in drug eluting stents – focus on the Endeavor® zotarolimus stent
title_fullStr Advances in drug eluting stents – focus on the Endeavor® zotarolimus stent
title_full_unstemmed Advances in drug eluting stents – focus on the Endeavor® zotarolimus stent
title_sort advances in drug eluting stents – focus on the endeavor® zotarolimus stent
publisher Dove Medical Press
publishDate 2008
url https://doaj.org/article/9551f77810bb4ed58f3f765e14708571
work_keys_str_mv AT jonathanbridges advancesindrugelutingstentsampndashfocusontheendeavorampregzotarolimusstent
AT donaldcutlip advancesindrugelutingstentsampndashfocusontheendeavorampregzotarolimusstent
_version_ 1718402720173391872